Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 16) analysis of randomized phase 2B study.
Jonathan Ian SilverbergAndreas PinterA AlaviC LyndeJean-David BouazizAndreas WollenbergD F MurrellS AlpizarV LaquerK ChaoucheF AhmadJ M ArmstrongChristophe PikettyPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2021)
Nemolizumab resulted in very rapid, sustained improvements of inflammation, pruritus and sleep in patients with EASI ≥ 16 at baseline.